SAN FRANCISCO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, ...
WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision” or the “Company”), a biotechnology company developing CRISPR-based therapies to cure viral infectious ...
Excision BioTherapeutics has so far released positive safety data from the first 3 participants living with HIV-1, with no evidence of vector shedding in sexual organ tissue. A cure for HIV-1 becomes ...
Results demonstrate safety, biodistribution, and on-target editing of simian immunodeficiency virus (SIV) in non-human primates Data are a key component of scientific rationale supporting the ongoing ...
SAN FRANCISCO, April 22, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious ...
Excision BioTherapeutics has become the first company to exclusively license new CRISPR systems discovered last year by Jennifer Doudna, Ph.D., a pioneer of the gene-editing technology, and Jillian ...
Excision’s foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at the University of California, Berkeley. For more ...
The Philly-based biotech company will begin human testing of EBT-101, a CRISPR-based gene editing construct developed at Temple’s Lewis Katz School of Medicine. According to Excision’s CEO, Daniel ...
Poster presentation to demonstrate EBT-107's potential to reduce clinically-relevant biomarkers and HBV DNA integration toward functional remission of chronic hepatitis B Oral presentation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback